Home/Pipeline/Next-Generation Influenza Vaccines

Next-Generation Influenza Vaccines

Influenza Prevention

Not DisclosedActive

Key Facts

Indication

Influenza Prevention

Phase

Not Disclosed

Status

Active

Company

Fluart Innovative Vaccines

About Fluart Innovative Vaccines

Fluart Innovative Vaccines is a pioneering Hungarian biotech with over 33 years of expertise in influenza vaccine development and manufacturing, having produced over 35 million doses. It leverages its GMP-certified facilities to provide full-spectrum CDMO services while advancing an innovative pipeline that includes next-generation influenza vaccines and bacteriophage therapies for antibiotic-resistant infections. The company is a recognized player in the global vaccine ecosystem, collaborating with international health organizations like the WHO and CDC.

View full company profile

Therapeutic Areas

Infectious Disease

Other Influenza Prevention Drugs

Drug	Company	Phase	Status
mRNA-based Broad Flu Vaccine	Micron Biomedical	Pre-clinical	Active
CaPtivaX Nasal Influenza Vaccine	CaPtivate Pharmaceuticals	Pre-clinical	Active
HD-MAP Influenza Vaccine	Vaxxas	Phase 2/3	Active
IRT Platform (e.g., Influenza)	Biological Mimetics	Research/Pre-clinical	Active
Replicon RNA Influenza Vaccine	BIKEN Group	Preclinical/Development	Partnership Development with VLPT Japan and Denka
Innovative Influenza Vaccine	Livzon Pharmaceutical	Phase 1	Completed patient enrollment in Phase I
CS-2606 mRNA Multi-valent Influenza Vaccine	CanSino Biologics	Pre-clinical	Active